CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab,...
Pharmaceutical
Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty...
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the...
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and...
Candel Therapeutics to Present at Upcoming Investor Conferences
NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distressWALTHAM, Mass.,...
Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy
Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048),...
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR)...
Compass Therapeutics to Participate in Upcoming May Investor Events
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release...
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
ASHBURN, Va., May 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage...
Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge...
Elsevier adds half a million records from ClinicalTrials.gov to Embase, enabling a seamless search experience in the world’s most comprehensive biomedical database
Data from studies conducted in more than 200 countries supports greater access to research and facilitates systematic reviews, clinical trial...
Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer
VALBY, Denmark, May 6, 2025 /PRNewswire/ -- H. Lundbeck A/S is pleased to announce its agreement with the Danish Centre for AI...
Fangzhou Launches Otsuka’s Third-Generation Leukemia Drug Ponatinib on its Platform
GUANGZHOU, China, May 5, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the...
Pulse Health Successfully Achieves ISO/IEC 27001 Certification
By achieving ISO/IEC 27001 certification, Pulse Health reinforces its commitment to the pharmaceutical industry - protecting client data and earning...
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®,...
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents
Company continues to expand global IP coverage and claims to major markets, now extending to June 2040 HOUSTON, May 05,...
Rose Hill Life Sciences Appoints Biopharma Veteran Jama Pitman as Strategic Advisor
Seasoned pharmaceutical executive to advise on clinical development, regulatory strategy, and commercialization as Company accelerates its psilocybin-based therapeutic programs BOSTON,...
Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer
VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),...